September 25, 2025Open Access

First real-world experience with 1L pembrolizumab and chemotherapy treatment for advanced triple-negative breast cancer in Poland: safety analysis and first survival outcomes from a multicenter cohort

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis of efficacy and safety outcomes in 89 Polish patients with PD-L1-positive mTNBC, indicating promising treatment effects.

Median progression-free survival was 9.3 months, with a notable correlation between metastatic sites and shorter PFS.
Adverse events occurred in 37.1% of patients, with one-third classified as grade 3/4, indicating manageable safety concerns.
The study assessed overall survival, with current data still immature; further follow-up is needed to evaluate long-term outcomes.
Clinical parameters had limited prognostic value, underscoring the need for integrating molecular biomarkers into treatment strategies.

Pieniążek et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis of efficacy and safety outcomes in 89 Polish patients with PD-L1-positive mTNBC, indicating promising treatment effects.